Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Companyâs product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPRAX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļPraxis Precision Medicines Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 16, 2020
āļāļĩāļāļĩāđāļSouza (Marcio)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ116
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 16
āļāļĩāđāļāļĒāļđāđ99 High Street, 30th Floor
āđāļĄāļ·āļāļBOSTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02110
āđāļāļĢāļĻāļąāļāļāđ16173008460
āđāļ§āđāļāđāļāļāđhttps://praxismedicines.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPRAX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 16, 2020
āļāļĩāļāļĩāđāļSouza (Marcio)
Mr. Alex Nemiroff, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
Ms. Jill Desimone
Independent Director
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Mr. Stuart A. Arbuckle
Independent Director
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Mr. Marcio Souza
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Jeffrey A. (Jeff) Chodakewitz, M.D.
Dr. Jeffrey A. (Jeff) Chodakewitz, M.D.
Independent Director
Dr. Merit Cudkowicz, M.D.
Dr. Merit Cudkowicz, M.D.
Independent Director
Mr. Timothy E. (Tim) Kelly
Mr. Timothy E. (Tim) Kelly
Chief Financial Officer
Mr. Dean Mitchell
Independent Chairman of the Board
Independent Chairman of the Board
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Alex Nemiroff, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
Ms. Jill Desimone
Independent Director
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Mr. Stuart A. Arbuckle
Independent Director
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Mr. Marcio Souza
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director